Rinnab L, Hessenauer A, Schütz S V, Schmid E, Küfer R, Finter F, Hautmann R E, Spindler K D, Cronauer M V
Klinik für Urologie und Kinderurologie, Universität Ulm, Ulm, Germany.
Urologe A. 2008 Mar;47(3):314-25. doi: 10.1007/s00120-008-1637-1.
The development of hormone-refractory prostate cancer cells is one of the major causes for the progression and high mortality rates in advanced prostate cancer (PCA). While the loss of the androgen receptor (AR) is the predominant mechanism for development of a hormone-insensitive disease in vitro, the first in vivo studies showed that the AR is still expressed or is even overexpressed in hormone-refractory PCA. In view of the increasing cases of PCA in the industrialized Western countries, a series of cell and molecular biological studies has led to the identification of various new factors and mechanisms that play a role during the development of hormone-refractory tumors. These findings should lead to the development of new therapeutic strategies.
激素难治性前列腺癌细胞的发展是晚期前列腺癌（PCA）进展和高死亡率的主要原因之一。虽然雄激素受体（AR）的缺失是体外激素不敏感疾病发展的主要机制，但首次体内研究表明，AR在激素难治性PCA中仍有表达甚至过度表达。鉴于工业化西方国家PCA病例不断增加，一系列细胞和分子生物学研究已导致识别出在激素难治性肿瘤发展过程中起作用的各种新因素和机制。这些发现应能推动新治疗策略的开发。
